ScinoPharm Taiwan Shares Owned By Institutions vs. Revenue
| 1789 Stock | TWD 22.20 0.50 2.20% |
For ScinoPharm Taiwan profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ScinoPharm Taiwan to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ScinoPharm Taiwan utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ScinoPharm Taiwan's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ScinoPharm Taiwan over time as well as its relative position and ranking within its peers.
ScinoPharm |
ScinoPharm Taiwan Revenue vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ScinoPharm Taiwan's current stock value. Our valuation model uses many indicators to compare ScinoPharm Taiwan value to that of its competitors to determine the firm's financial worth. ScinoPharm Taiwan is number one stock in shares owned by institutions category among its peers. It also is the top company in revenue category among its peers totaling about 163,839,561 of Revenue per Shares Owned By Institutions. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ScinoPharm Taiwan's earnings, one of the primary drivers of an investment's value.ScinoPharm Revenue vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
ScinoPharm Taiwan |
| = | 16.86 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
ScinoPharm Taiwan |
| = | 2.76 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
ScinoPharm Revenue vs Competition
ScinoPharm Taiwan is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 883.89 Billion. ScinoPharm Taiwan adds roughly 2.76 Billion in revenue claiming only tiny portion of equities under Health Care industry.
ScinoPharm Taiwan Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ScinoPharm Taiwan, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ScinoPharm Taiwan will eventually generate negative long term returns. The profitability progress is the general direction of ScinoPharm Taiwan's change in net profit over the period of time. It can combine multiple indicators of ScinoPharm Taiwan, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. ScinoPharm Taiwan, Ltd. was founded in 1997 and is headquartered in Tainan, Taiwan. SCINOPHARM TAIWAN operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.
ScinoPharm Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ScinoPharm Taiwan. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ScinoPharm Taiwan position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ScinoPharm Taiwan's important profitability drivers and their relationship over time.
Use ScinoPharm Taiwan in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ScinoPharm Taiwan position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ScinoPharm Taiwan will appreciate offsetting losses from the drop in the long position's value.ScinoPharm Taiwan Pair Trading
ScinoPharm Taiwan Pair Trading Analysis
The ability to find closely correlated positions to ScinoPharm Taiwan could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ScinoPharm Taiwan when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ScinoPharm Taiwan - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ScinoPharm Taiwan to buy it.
The correlation of ScinoPharm Taiwan is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ScinoPharm Taiwan moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ScinoPharm Taiwan moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ScinoPharm Taiwan can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ScinoPharm Taiwan position
In addition to having ScinoPharm Taiwan in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Disruptive Technologies Thematic Idea Now
Disruptive Technologies
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for ScinoPharm Stock Analysis
When running ScinoPharm Taiwan's price analysis, check to measure ScinoPharm Taiwan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ScinoPharm Taiwan is operating at the current time. Most of ScinoPharm Taiwan's value examination focuses on studying past and present price action to predict the probability of ScinoPharm Taiwan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ScinoPharm Taiwan's price. Additionally, you may evaluate how the addition of ScinoPharm Taiwan to your portfolios can decrease your overall portfolio volatility.